It’s not big news that most of America is tired. Wherever your look people are yawning – in the car, in the office, in front of the TV – Americans seem to be tired all the time.
Ed Price, President of PCI Synthesis, issues his annual list of trends that he feels will...
A reminder to pharma manufacturers, the Drug Supply Chain Security Act (DSCSA) deadlines are...
People want it all, don’t they? The type of cars many drive is one indicator. ...
Enhancing the flexibility of operations is swiftly becoming a major priority for pharmaceutical manufacturers. In Accenture’s 2013 marketing study of leading manufacturers, 82 percent of respondents agreed “the ability to flexibly and dynamically move product from one facility to another or to change the product mix at an existing facility to match demand is critical to achieving our growth goals.”
As processes, procedures and perceptions have matured the apparent risks associated with manual cleaning have become a frequently discussed topic throughout the pharmaceutical industry.
The global pharmaceutical industry will reach nearly $1.2 trillion in sales by 2017, representing a growth rate of up to 6 percent per year, according to The IMS Institute for Healthcare Informatics. To remain competitive in this growing market, pharmaceutical manufacturers are continually looking to evolve their operations to keep up with today’s trends, create greater efficiencies and comply with the newest regulations.
The need to manage environment, health and safety (EHS) performance across our organizations and throughout our global plants has never been more apparent. While considerations of EHS performance were once limited to one organization’s performance within its four walls, things have changed.
Since 2011 I have postulated that pharma needs a “creative destructionist” for its manufacturing technology innovations to get out from its archaic “quality by analysis” methods to “quality from the get go methods”. Current practices have cost patients billions in excessive costs. Generally most of the “creative destructionists” are from outside the industry, McLaren could be the one for the pharma and the chemical industry.
As drug delivery technologies, such as syringes and inhalers, evolve pharmaceutical manufacturers are tasked with upholding the highest standard of quality, while still maintaining or improving efficiency. Their success in this regard is largely predicated on the flexibility of their operations and the degree to which they proactively work with suppliers to improve their lines.
At LNS Research we believe in the expression “you can’t control what you don’t measure.” With that, we’ve focused a significant part of our research on identifying the “Metrics That Matter.” And one of the topics of we find of most interest to our Global Executive Council is benchmarking and understanding how to measure performance.
In an increasingly complex and challenging climate, chemical companies are facing a combination of shifting market forces and an increasingly heterogeneous customer set. Many organizations are focusing solely on all-out growth or across-the-board cost-cutting strategies in an attempt to adjust course.
I am grateful for many things in my life. But one thing that I just added to my list, and never considered before, is that I don’t have to figure out the shopping habits of American consumers.
In recent years genetic testing has been introduced. It has caused a bit of for and against uproar. Information from this testing could be used for changing the lifestyle that could avert diseases one might encounter with age or even could be used for personalized medicine. Better lifestyle could lower pharma sales and an unacceptable scenario by the current players.
Scaling up can be a challenge; know the processes and tools for a successful transition.
In 2005 I had raised a question about Batch or a Continuous Process: A Choice. At that time it seemed like a logical question and still is. However, I left part of the question unanswered. Missing was the discussion of components of pharma manufacturing, API manufacture and their formulations.
There has always been much hand-wringing and shouting regarding the costs of new medications. Most of this comes from people outside the industry – politicians, public health advocates, and a smattering of those that just like to hear themselves talk.
Humans are a strange lot. We are more than willing to believe just about any product claim in the hopes that an easy solution to our problem can be found inside a pill, tablet or liquid.
In an ideal world, OpenFDA could usher in a world of new and improved tools and products that would improve patient safety and adherence, increase physician awareness of drug safety dangers, assist healthcare decision makers who are driving prescribing behavior with better decision support, and lower the overall cost of care by reducing avoidable side effects. But we don’t live in an ideal world.